Review Article

New pharmacological strategies in some metabolic endocrine disorder under a toxicological approach

Luisetto M*, Ghulam Rasool Mashori and Cabianca luca

Published: 09 March, 2018 | Volume 2 - Issue 1 | Pages: 015-021

In this review After Observing biomedical literature (starting from some heart disease) results that some pathological phenomena are deeply involved in some metabolic endocrine condition: Kinetics and gradients in metabolism, catabolism, time related, toxic like effect, electrical cell membrane status, smooth vascular muscle cell hyper-reactivity, platelet iperactivations, central autonomic control after acute stroke, great electrolytes unbalances et other factors as pro-hypertrophic signaling and oxidative stress. Observing actual current therapy in some metabolic endocrine therapy often is used association of drugs (in example in type II diabetes). In Many other pathologies efficacy drug therapy exist, and often only 1 pharmacological molecule resolve the pathological condition. But in many disease even associating 2-3-4 drugs the % of cure not increase (efficacy, effectiveness). It mean that this drugs strategies are not the really best? Or it mean a low active level? Why for this pathological condition this association drugs in currently use not do the right works as really needed? There is the need for new really efficacy drugs strategy that show a profile of efficacy as requested in order to resolve the pathological condition? Or to be added to the actual therapy? The actual pharmacological strategies in some metabolic endocrine disorder is really the best? Or other strategies can be introduced?

Read Full Article HTML DOI: 10.29328/journal.acem.1001006 Cite this Article Read Full Article PDF


Metabolic-endocrine disease; New pharmacological strategies; Toxicology; Antidotes approach; kinetics


  1. Luisetto M, Luca C, Farhan AK, Ghulam RM. Sudden Heart Pathology-a New Research Hipotesys in Drug Design strategy. Mod Appro Drug Des. 2017; 8: 555730. Ref.: https://goo.gl/uKLqCu
  2. luisetto M, Ahmadabadi BN, Mashori GR. Heart disease new hypotesys:under endogenous toxicological aspect. J Cardiol Cardiovasc Med. 2018; 3: 001-004. Ref.: https://goo.gl/zmW7uG
  3. Luisetto M. Intra- Local Toxicology Aspect Time Related in Some Pathologic Conditions. Open Acc J of Toxicol. 2017; 2: 002 555586. Ref.: https://goo.gl/ghchpJ
  4. Luisetto M, Nili-Ahmadabadi Bm, Mashori GR. Surgery and new Pharmacological strategy in some atherosclerotic chronic and acute conditions. Arch Surg Clin Res. 2017; 1: 042-048. Ref.: https://goo.gl/xYWA29
  5. Katritsis DG, Gersh BJ, Camm AJ. A Clinical Perspective on Sudden Cardiac Death. Arrhythm Electrophysiol Rev. 2016; 5: 177-182. Ref.: https://goo.gl/xoti5Z
  6. Hung MJ, Hu P, Hung MY. Coronary artery spasm: review and update. Into J Med Sci. 2014; 11: 1161-1171. Ref.: https://goo.gl/hc7ZvS
  7. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease. Circulation. 2012; 125: 1043-1052. Ref.: https://goo.gl/bf2HZa
  8. Sörös P, Hachinski V. Cardiovascular and neurological causes of sudden death after ischemic stroke. Lancet Neurol. 2012; 11:179-188. Ref.: https://goo.gl/5xrqMg
  9. Avila MD, Escolar E, Lamas GA. Chelation therapy after the Trial to Assess Chelation Therapy: results of a unique trial. Curr Opin Cardiol. 2014; 29: 481-488. Ref.: https://goo.gl/Vk9bkr
  10. Buxton AE. Sudden death in ischemic heart disease-2017. Int JCardiol. 2017; 237: 64-66. Ref.: https://goo.gl/7FvKnS
  11. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017; 377: 41-51. Ref.: https://goo.gl/tgokvo
  12. Goldberg IJ, Trent CM, Schulze PC. Lipid Metabolism and Toxicity in the Heart. Cell Metab. 2012; 15: 805-812. Ref.: https://goo.gl/3vbe6d
  13. Mladěnka P, Applová L, Patočka J, Costa VM, Remiao F, et al. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018. Ref.: https://goo.gl/282h1J
  14. Trang A, Aguilar D. Treating Disease Mechanisms in Patients with Heart Failure and Diabetes Mellitus. Curr Heart Fail Rep. 2017; 14: 445-453. Ref.: https://goo.gl/xGt3U3
  15. Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, et al. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care. 2017; 40: 1763-1770. Ref.: https://goo.gl/LjdQeR
  16. Dziubak A, Wójcicka G. The pathophysiological basis of the protective effects of metformin in heart failure. Postepy Hig Med Dosw (Online). 2017; 71: 773-787. Ref.: https://goo.gl/r3oekn
  17. Editorial Efficacy of Oncologic Drug Therapy Some to Rethink in the Management of the System? Journal of business management and economics. JBME luisetto m
  18. Arora S, Probst MA, Andrews L, Camilion M, Grock A, et al. A randomized, controlled trial of oral versus intravenous fluids for lowering blood glucose in emergency department patients with hyperglycemia. CJEM. 2014; 16: 214-219. Ref.: https://goo.gl/7A3XEo
  19. Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, et al. Low Water Intake and Risk for New-Onset Hyperglycemia. Diabetes Care. 2011; 34: 2551-2554. Ref.: https://goo.gl/LCiw1q

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?